Biomarkers, surrogate end points, and the ac... [Clin Cancer Res. 2004] - PubMed

Related citations

Review Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. [Clin Cancer Res. 2004]
Review Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Clin Cancer Res. 2004 Jun 1; 10(11):3885-96.
Review Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. [Cancer Epidemiol Biomarkers Prev. 2000]
Review Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):127-37.
Review Promises of biomarkers in drug development--a reality check. [Chem Biol Drug Des. 2007]
Review Promises of biomarkers in drug development--a reality check.
Marrer E, Dieterle F. Chem Biol Drug Des. 2007 Jun; 69(6):381-94.
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. [Cancer Epidemiol Biomarkers Prev. 2003]
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. [Clin Pharmacol Ther. 2009]
Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.
Fine BM, Amler L. Clin Pharmacol Ther. 2009 May; 85(5):535-8. Epub 2009 Mar 18.

See reviews... See all...

Cited by 6 PubMed Central articles

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. [Clin Cancer Res. 2010]
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, et al. Clin Cancer Res. 2010 Nov 15; 16(22):5447-57. Epub 2010 Oct 5.
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. [Proc Natl Acad Sci U S A. 2007]
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Proc Natl Acad Sci U S A. 2007 Oct 23; 104(43):17069-74. Epub 2007 Oct 17.
Review Biomarker method validation in anticancer drug development. [Br J Pharmacol. 2008]
Review Biomarker method validation in anticancer drug development.
Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Br J Pharmacol. 2008 Feb; 153(4):646-56. Epub 2007 Sep 17.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Biomarkers, surrogate end points, and the acceleration of drug development for c...
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
Clin Cancer Res. 2004 Jun 1 ;10(11):3881-4.

PubMed
Rapid detection of active and latent tuberculosis infection in HIV-positive indi...
Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells.
AIDS. 2002 Nov 22 ;16(17):2285-93.

PubMed
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP.
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP.
Nature. 1999 Sep 9 ;401(6749):173-7.

PubMed
Molecular genetics of meningiomas: from basic research to potential clinical app...
Molecular genetics of meningiomas: from basic research to potential clinical applications.
Neurosurgery. 2007 May ;60(5):787-98; discussion 787-98.

PubMed
Arginine metabolism: boundaries of our knowledge.
Arginine metabolism: boundaries of our knowledge.
J Nutr. 2007 Jun ;137(6 Suppl 2):1602S-1609S.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Source

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information